This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC0Q1B5_M.jpg
Mylan announced earnings per share of $0.9 on revenue of $2.62B. Analysts polled by Investing.com anticipated EPS of $0.87 on revenue of $2.65B. That with comparison to EPS of $0.82 on revenue of $2.5B in the same period a year before. Mylan had reported EPS of $1.4 on revenue of $3.19B in the previous quarter. Analysts are expecting EPS of $1.02 and revenue of $2.83B in the upcoming quarter.
Mylan shares are down 12.59% from the beginning of the year , still down 23.97% from its 52 week high of $23.11 set on February 6. They are under-performing the S&P 500 which is down 9.7% year to date.
Mylan shares gained 0.28% in pre-market trade following the report.
Mylan’s report follows an earnings beat by J&J on April 14, who reported EPS of $2.3 on revenue of $20.69B, compared to forecasts EPS of $2.02 on revenue of $19.73B.
Pfizer had beat expectations on April 28 with first quarter EPS of $0.8 on revenue of $12.03B, compared to forecast for EPS of $0.73 on revenue of $11.81B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
